Time Commitment: 4 hours and 30 minutes over 56 days
Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC Points

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login



Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Petros Grivas

UW/Fred Hutch

Dr. Petros Grivas is board-certified medical oncologist with vast experience and high expertise in genitourinary (GU) cancers. He is the Clinical Director of the GU Cancers Program and Professor at the Dept. of Medicine, Division of Hematology Oncology, University of Washington and at Clinical Research Division at Fred Hutchinson Cancer Center. He received M.D. and Ph.D. in Greece in 2005 and 2009, respectively. He completed Internal Medicine Residency at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia) in 2010, and Hematology/Oncology Fellowship at University of Michigan (Ann Arbor) in 2013. He was Clinical Lecturer before he was recruited as Assistant Professor at Cleveland Clinic (Cleveland). He has had main role in several clinical trials leading to FDA approval of new drugs for urothelial cancer. He is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists and other healthcare providers, mentoring numerous trainees, leading large innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research. He is dedicated to personalized and outstanding patient care, efficient clinical operations, and believes in optimal patient-physician relationship as well as community outreach.